[The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
The daily administration of 25 mg effervescent granules is about equipotent with a daily dose of 200 mg allopurinol, giving due attention to the caution necessary for uricosuric therapy. The daily administration of 50 mg benzbromarone effervescent granules has a slight but significantly greater uric acid-lowering effect than treatment with 300 mg allopurinol per day. The tolerance of benzbromarone in the active form named was good in all cases. Side effects were not observed. Since benzbromarone as effervescent granules is taken with plenty of fluid this takes care of an increased fluid intake and introduces a motivation for doing so.
D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use*; D001553:Benzbromarone / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D004304:Dosage Forms; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents
D001572:Benzofurans; D004304:Dosage Forms; D014528:Uricosuric Agents; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol
Harnsäuresenkende Wirkung von Benzbromaron-Brausegranulat und Allopurinol Vergleichende Untersuchungen.